<?xml version="1.0" encoding="UTF-8"?>
<p>There is considerable debate as to when HAART should be initiated, since the benefits of early treatment can be counteracted by antiviral drug toxicity
 <xref ref-type="bibr" rid="b34">34</xref>. Here, we assume that at the end of the latent stage, an individual enters HAART with probability 
 <italic>ρ</italic>, where 
 <italic>ρ</italic> represents treatment coverage. HAART lengthens life, facilitates relative reduction in transmission, and improves the utility that an HIV− individual associates with unprotected sex, by an additive factor 
 <italic>d</italic> (see 
 <xref ref-type="supplementary-material" rid="S1">Supplementary material</xref>). Since HAART availability improves the 
 <italic>U</italic>
 <sub>
  <italic>US</italic>
 </sub>, it affects whether individuals offer, or accept, unprotected sex, and hence it may influence the perceived risk parameter, 
 <italic>b</italic>.
</p>
